Neurocrine biosciences announces initiation of phase 1 clinical study evaluating effects of nbi-1065890, a second-generation vmat2 inhibitor, in healthy adults

San diego , march 28, 2024 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix), today announced the initiation of its phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of investigational compound nbi-1065890 in healthy adult participants. nbi-1065890 is an investigational, oral, selective inhibitor of the vesicular monoamine transporter-2 (vmat2) for the potential treatment of certain neurological and neuropsychiatric conditions.
NBIX Ratings Summary
NBIX Quant Ranking